Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

March 23, 2021

Study Completion Date

August 13, 2023

Conditions
Bladder Cancer
Interventions
DRUG

Avelumab

"Induction phase:~* once weekly for weeks 1-6,~* once every 2 weeks at week 8, 10, and 12~Maintenance phase:~* Once every week for weeks 1-3~* Once every 2 weeks starting at week 5, until the next BCG treatment"

BIOLOGICAL

BCG

"Induction phase (cycle 1):~• Once weekly for weeks 1-6~Maintenance phase (Month 3, 6, and 12):~• Once weekly for 3 weeks"

Trial Locations (1)

73104

Stephenson Cancer Center, Oklahoma City

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

EMD Serono

INDUSTRY

lead

University of Oklahoma

OTHER

NCT03892642 - Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter